New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
08:00 EDTAEGRAegerion subpoena not a 'major surprise,' says Leerink
Leerink views the Aegerion's subpoena from the U.S. Department of Justice as not a "major surprise" after the FDA reprimanded the company for statements made by its CEO on CNBC that suggested Juxtapid can improve patient survival, which has not been studied in clinical trial. The firm expects the subpoena will result in more rigorous marketing practices controlled by compliance and a “manageable fine" and reiterates an Outperform rating on Aegerion.
News For AEGR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for AEGR

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use